148 related articles for article (PubMed ID: 21763166)
1. Development of in silico models for pyrazoles and pyrimidine derivatives as cyclin-dependent kinase 2 inhibitors.
Wang F; Ma Z; Li Y; Zhu S; Xiao Z; Zhang H; Wang Y
J Mol Graph Model; 2011 Sep; 30():67-81. PubMed ID: 21763166
[TBL] [Abstract][Full Text] [Related]
2. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
[TBL] [Abstract][Full Text] [Related]
3. Pharmacophore filtering and 3D-QSAR in the discovery of new JAK2 inhibitors.
Dhanachandra Singh Kh; Karthikeyan M; Kirubakaran P; Nagamani S
J Mol Graph Model; 2011 Sep; 30():186-97. PubMed ID: 21831680
[TBL] [Abstract][Full Text] [Related]
4. Exploring the structure requirement for PKCθ inhibitory activity of pyridinecarbonitrile derivatives: an in silico analysis.
Li Y; Hao M; Ren H; Zhang S; Wang X; Ma M; Li G; Yang L
J Mol Graph Model; 2012 Apr; 34():76-88. PubMed ID: 22306416
[TBL] [Abstract][Full Text] [Related]
5. Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.
Dwyer MP; Paruch K; Alvarez C; Doll RJ; Keertikar K; Duca J; Fischmann TO; Hruza A; Madison V; Lees E; Parry D; Seghezzi W; Sgambellone N; Shanahan F; Wiswell D; Guzi TJ
Bioorg Med Chem Lett; 2007 Nov; 17(22):6216-9. PubMed ID: 17904366
[TBL] [Abstract][Full Text] [Related]
6. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ
Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
[TBL] [Abstract][Full Text] [Related]
7. 3D-QSAR CoMFA study on indenopyrazole derivatives as cyclin dependent kinase 4 (CDK4) and cyclin dependent kinase 2 (CDK2) inhibitors.
Singh SK; Dessalew N; Bharatam PV
Eur J Med Chem; 2006 Nov; 41(11):1310-9. PubMed ID: 16890327
[TBL] [Abstract][Full Text] [Related]
8. An efficient tool for identifying inhibitors based on 3D-QSAR and docking using feature-shape pharmacophore of biologically active conformation--a case study with CDK2/cyclinA.
Mascarenhas NM; Ghoshal N
Eur J Med Chem; 2008 Dec; 43(12):2807-18. PubMed ID: 18037537
[TBL] [Abstract][Full Text] [Related]
9. 3D-QSAR and molecular docking studies of 2-pyrimidinecarbonitrile derivatives as inhibitors against falcipain-3.
Potshangbam AM; Tanneeru K; Reddy BM; Guruprasad L
Bioorg Med Chem Lett; 2011 Dec; 21(23):7219-23. PubMed ID: 22018459
[TBL] [Abstract][Full Text] [Related]
10. 3D-QSAR and docking studies on pyrazolo[4,3-h]qinazoline-3-carboxamides as cyclin-dependent kinase 2 (CDK2) inhibitors.
Lan P; Chen WN; Xiao GK; Sun PH; Chen WM
Bioorg Med Chem Lett; 2010 Nov; 20(22):6764-72. PubMed ID: 20869873
[TBL] [Abstract][Full Text] [Related]
11. Exploring the selectivity of a ligand complex with CDK2/CDK1: a molecular dynamics simulation approach.
Tripathi SK; Singh SK; Singh P; Chellaperumal P; Reddy KK; Selvaraj C
J Mol Recognit; 2012 Oct; 25(10):504-12. PubMed ID: 22996593
[TBL] [Abstract][Full Text] [Related]
12. Molecular docking/dynamics studies of Aurora A kinase inhibitors.
Talele TT; McLaughlin ML
J Mol Graph Model; 2008 Jun; 26(8):1213-22. PubMed ID: 18096419
[TBL] [Abstract][Full Text] [Related]
13. Combined 3D-QSAR modeling and molecular docking study on 1,4-dihydroindeno[1,2-c]pyrazoles as VEGFR-2 kinase inhibitors.
Zeng H; Zhang H
J Mol Graph Model; 2010 Aug; 29(1):54-71. PubMed ID: 20471293
[TBL] [Abstract][Full Text] [Related]
14. 3D-QSAR CoMFA and CoMSIA study on benzodipyrazoles as cyclin dependent kinase 2 inhibitors.
Dessalew N; Singh SK
Med Chem; 2008 Jul; 4(4):313-21. PubMed ID: 18673142
[TBL] [Abstract][Full Text] [Related]
15. Studies of tricyclic piperazine/piperidine furnished molecules as novel integrin αvβ3/αIIbβ3 dual antagonists using 3D-QSAR and molecular docking.
Yan Y; Li Y; Zhang S; Ai C
J Mol Graph Model; 2011 Feb; 29(5):747-62. PubMed ID: 21273104
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of novel pyrimidine derivatives as CDK2 inhibitors.
Ibrahim DA; El-Metwally AM
Eur J Med Chem; 2010 Mar; 45(3):1158-66. PubMed ID: 20045222
[TBL] [Abstract][Full Text] [Related]
17. Computational study on the interaction of N1 substituted pyrazole derivatives with B-raf kinase: an unusual water wire hydrogen-bond network and novel interactions at the entrance of the active site.
Alzate-Morales JH; Vergara-Jaque A; Caballero J
J Chem Inf Model; 2010 Jun; 50(6):1101-12. PubMed ID: 20524689
[TBL] [Abstract][Full Text] [Related]
18. Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)-pyrimidines in complexes with CDK2 and CDK7.
Chohan TA; Qian HY; Pan YL; Chen JZ
Mol Biosyst; 2016 Jan; 12(1):145-61. PubMed ID: 26565382
[TBL] [Abstract][Full Text] [Related]
19. Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors.
Zhang G; Ren Y
Molecules; 2018 Nov; 23(11):. PubMed ID: 30423939
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as anti-proliferative CDK2 inhibitors.
Ibrahim DA; Ismail NS
Eur J Med Chem; 2011 Dec; 46(12):5825-32. PubMed ID: 22000924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]